Angle Plc notes >>>18 Nov 2024 10:37
A few years back Angle raised a load of money to promote the selling of their new Parsortix machine. It can catch live circulating tumour cells (CTC's) which can then be analysed for up to date information about a person’s cancer. Sales of the machine were very disappointing, and a load of money was lost. Reason being developing the assays (tests) to analyse the CTC's is very expensive. Large Pharma Co's for the most part clearly were not willing to spend the money (thus putting cancer research back months if not more than a year IMHO). Shame on them. So, Angle was forced to do the assays themselves, and here we are. Eisai Inc. and Astrazeneca thus far are Angle's main clients. The data from studies over the last few years puts Angle in a fantastic position now. In fact, I suspect as they themselves use the Parsortix machine as a service to the industry there is a chance Angle may stop selling them as other Co's could (if they spent the money!) do their own assays and so compete with Angle............!
All IMHO.